Caplin Point Laboratories
Market cap ₹15,851 Cr
- P/E
- 23.07
- Day range
- ₹2,072.00 – ₹2,239.60
- 52-week range
- ₹1,500.30 – ₹2,990.00
- Volume
- 7.10 L
- Open
- ₹2,231.00
- Prev close
- ₹2,247.10
Latest results · Q2 FY27(consolidated)Revenue ₹630 Cr+17.9%Profit ₹182 Cr+13.8%Margin 29.0%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
CAPLIPOINT in NSE indices and F&O
Research profile
Composite 59 / 100Factor percentiles
Derived metrics
- Earn. yield
- 4.3%
- Graham no.
- ₹954.84
- vs Graham
- -54.2%
- ROE ÷ P/B
- 4.6%
- 12-1 mom.
- +18.4%
- Return / vol
- 0.21
- Magic Formula
- #95
- Piotroski
- 3/6
- FCF yield
- 1.7%
- PEG
- 1.21
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Caplin Point LaboratoriesCAPLIPOINT | ₹15,851 Cr | 23.07 | 4.66 | 21.7% | 24.0% | 35.0% | 0.00 | +18.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 10h agoHeadlines about Caplin Point Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 23.0
- Price / Book
- 4.06
- ROE (FY26)
- 21.7%
- ROCE (latest year)
- 24%
- Dividend yield
- 0.38%
Moving averages (NSE)
- 20-day
- ₹2,339.08
- Price below
- 50-day
- ₹2,516.98
- Price below
- 200-day
- ₹2,196.66
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 | 630 |
| Expenses | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 | 407 |
| Operating Profit | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 | 223 |
| OPM % | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% | 35% |
| Other Income | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 | 33 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 | 23 |
| Profit before tax | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 | 233 |
| Tax % | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% | 22% |
| Net Profit | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 | 182 |
| EPS in Rs | ₹15.43 | ₹16.01 | ₹16.31 | ₹17.21 | ₹18.28 | ₹18.76 | ₹20.10 | ₹20.32 | ₹21.56 | ₹22.38 | ₹23.27 | ₹23.43 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+42 days since Mar 2021
+42 days since Mar 2021
+57 days since Mar 2021
+28 days since Mar 2021
+54 days since Mar 2021
Strengths, risks & growth
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
- Company's median sales growth is 19.9% of last 10 years
Risks
None flagged by the checklist.
Compounded Sales Growth
- 10 Years
- +25%
- 5 Years
- +16%
- 3 Years
- +14%
- TTM
- +17%
Compounded Profit Growth
- 10 Years
- +30%
- 5 Years
- +21%
- 3 Years
- +19%
- TTM
- +17%
Stock Price CAGR
- 10 Years
- +20%
- 5 Years
- +20%
- 3 Years
- +18%
- 1 Year
- +8%
Return on Equity
- 10 Years
- +25%
- 5 Years
- +23%
- 3 Years
- +22%
- Last Year
- +21%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 70.57% | 70.57% | 70.57% | 70.57% | 0.00 pp |
| FII | 6.58% | 6.15% | 5.76% | 5.72% | -0.04 pp |
| DII | 2.05% | 2.14% | 2.49% | 2.20% | -0.29 pp |
| Public | 20.81% | 21.14% | 21.19% | 21.52% | +0.33 pp |
Filed with NSE for Sept 2026: promoters 70.57%, public 29.43%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 1.64% (-0.39 pp)- Promoters70.6%
- Foreign institutions5.7%
- Mutual funds1.6%
- Insurance0.1%
- Other domestic institutions0.5%
- Retail13.8%
- Others7.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| UTI Small Cap Fund | 0.45% | 1.61% | -0.12 pp |
| UTI Large & Mid Cap Fund | 0.32% | 0.93% | -0.24 pp |
| UTI Aggressive Hybrid Fund | 0.25% | 0.70% | -0.27 pp |
| UTI Healthcare Fund | 0.21% | 2.68% | -1.27 pp |
| Nippon India Nifty Smallcap 250 Index Fund | 0.04% | 0.22% | -0.01 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 35.2%
- Downside volatility
- 34.0%
- Worst 5% of days
- 3.5%
- Average of that tail
- 5.1%
- Max drawdown (1Y)
- 35.8%
- Below its peak
- 27.3%
Against the market
- Beta vs Nifty 50
- 0.81
- Correlation
- 0.31
- Relative strength (3M)
- -21.2%
- ATR (14)
- 4.9%
Return
- Return 1M
- -9.4%
- Return 3M
- -17.3%
- Return 6M
- +5.0%
- Return 1Y
- +7.3%
- vs 200-day average
- -5.1%
Momentum
- RSI (14) · oversold
- 29.8
- MACD histogram
- -13.42
- Stochastic %K
- 2.5
- ADX (14)
- 19.9
- +DI / −DI
- 18.0 / 37.9
- Money flow index
- 20.6
Participation
- Delivery (20d avg)
- 44.7%
- vs its 60-day baseline
- +4.3 pts
- Volume vs 20-day
- +6.1σ
- Close vs day's VWAP
- -0.8%
- 52-week position
- 43 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹275 Cr
- FCF yield
- 1.7%
- Cash conversion
- 0.81
- Accruals ratio
- 0.031
- Net debt
- -₹601 Cr
- Net debt / equity
- -0.17
- EV / sales
- 6.40
- PEG
- 1.21
- Capex intensity
- 11.3%
- Revenue CAGR
- 19.4%
- Profit CAGR
- 19.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹4.00
Dividend - Rs 4 Per Share
18 Sept 2026ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
29 May 2026ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
12 Sept 2025ex-date - dividend₹3.00
Interim Dividend - Rs 3 Per Share
30 May 2025ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
23 Sept 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Sept 2024ex-date - dividend₹2.50
Interim Dividend - Rs 2.50 Per Share
31 May 2024ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
14 Sept 2023ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
9 Jun 2023ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
21 Sept 2022ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
23 May 2022ex-date - dividend₹1.50
Annual General Meeting/Dividend - Rs 1.50 Per Share
20 Sept 2021ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
18 May 2021ex-date - dividend₹0.40
Annual General Meeting/Dividend - Rs 0.40 Per Share
21 Sept 2020ex-date - dividend₹2.10
Interim Dividend - Rs 2.10 Per Share
12 Mar 2020ex-date - dividend₹2.20
Annual General Meeting/Dividend - Rs 2.20 Per Share
4 Sept 2019ex-date - dividend₹2.00
Annual General Meeting/Dividend- Rs 2 Per Share
18 Sept 2018ex-date - dividend₹1.50
Annual General Meeting/Dividend - Rs 1.50 Per Share
7 Sept 2017ex-date - otherNot available — not reported in this filing
Fv Splt Frm Rs 10 To Rs 2
19 Oct 2016ex-date - dividend₹3.50
Annual General Meeting/Dividend - Rs 3.50 Per Share
1 Sept 2016ex-date
Company announcements
Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.
Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.
Voting Results and Scrutinizer Report for the 35th Annual General Meeting
Proceedings of 35th Annual General Meeting of the Company
Clarification with respect to Volume Movement
The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Newspaper Publication for Notice of 35th AGM and E-Voting Information
Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-26
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Notice of the 35th Annual General Meeting of the Company
Annual Report for the Financial Year 2025-26
Newspaper Publication for convening 35th AGM of the Company through Video Conferencing.
Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company's subsidiary)
Transcript for Earnings call- Q1- FY 2026-27
Filed with BSE (scrip 524742); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026SlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Caplin Point Laboratories: common questions
Answered from the figures on this page.